MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
its financial results for the fiscal quarter ended March 31,
2017. A copy of the press release is furnished as Exhibit 99.1 to
this report and is incorporated herein by reference.
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act.
| 99.1 |
Press Release of the Company dated April 27, 2017
|
About MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO)
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia. MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO) Recent Trading Information
MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO) closed its last trading session down -0.23 at 14.77 with 700,171 shares trading hands.
